Natalizumab

Introduction Overview

Generic Name

natalizumab

Brand Name

Tysabri

Dosage Form

Intravenous infusion

Drug Class

Selective immunosuppressants (Integrin receptor antagonists, Monoclonal antibody)

Pharmacokinetics

Absorption: Natalizumab (Tysabri) is administered exclusively via intravenous infusion, bypassing the gastrointestinal tract and hence absorption processes characteristic of oral medications are not applicable. Upon administration, bioavailability is effectively 100%, as the drug directly enters systemic circulation. Absorption kinetics relate chiefly to infusion rates and complete delivery over approximately one hour to minimize infusion reactions.

Distribution: Natalizumab is a large monoclonal antibody molecule (approximately 149 kDa) and distributes predominantly within the vascular and interstitial compartments. Due to its size, it does not readily cross cell membranes but can penetrate inflamed tissues where integrin receptors are expressed. The volume of distribution approximates the plasma volume with limited penetration beyond the vascular and interstitial spaces. Binding is selective to alpha-4 integrins on leukocytes, localizing its action primarily to immune cells circulating or migrating through blood and tissues.

Metabolism: As a monoclonal antibody, natalizumab is catabolized primarily via proteolytic degradation within the reticuloendothelial system into small peptides and amino acids. This process occurs systemically and is independent of cytochrome P450 enzymes, minimizing metabolic interactions common with small molecule drugs. Clearance is influenced by target-mediated elimination due to binding to integrin receptors and typical immunoglobulin recycling processes.

Elimination: The elimination half-life of natalizumab is approximately 11 days, with dosing at 4-week intervals to maintain therapeutic plasma concentrations. Clearance mechanisms include cellular catabolism of bound and unbound antibody molecules. Because of its long half-life, steady-state concentrations are generally reached after several doses. Renal excretion is negligible owing to the molecular size, and hepatic metabolism is not pertinent to elimination. Patient factors such as anti-natalizumab antibody formation can influence clearance and efficacy.

Dosage Forms

Available Dosage Forms:
- Single-Dose Vial: 300 mg/15 mL (20 mg/mL) solution for intravenous infusion
- Biosimilar product (Tyruko) also available in the same formulation and strength

Dosages for Adults and Adolescents:
- Multiple Sclerosis (MS): 300 mg IV infusion over approximately 1 hour every 4 weeks
- Crohn's Disease (CD): 300 mg IV infusion over approximately 1 hour every 4 weeks as maintenance therapy

Specific Patient Populations:
- Pediatric Use: Not approved for use in individuals younger than 18 years
- Renal/Hepatic Impairment: No specific dosage adjustment necessary; clearance not influenced by renal or hepatic function
- Special Monitoring: Requires enrollment and treatment under REMS program (TOUCH Prescribing Program) to monitor for risk of progressive multifocal leukoencephalopathy (PML)

Administration Notes:
- Infusion must be performed by a healthcare professional in a controlled medical setting
- Patients are monitored during infusion and for at least 1 hour post-infusion for hypersensitivity or other adverse reactions
- Initial MRI recommended prior to treatment to rule out existing brain infection
- Screening for John Cunningham Virus (JCV) antibodies advised to stratify risk of PML
- Use is contraindicated with concomitant immunosuppressants or TNF-alpha inhibitors in Crohn’s disease patients
- Oral corticosteroid tapering is recommended if steroids are used concomitantly

Mechanism Of Action

Natalizumab is a humanized monoclonal antibody that selectively targets the alpha-4 subunit of alpha-4 beta-1 (very late antigen-4) and alpha-4 beta-7 integrins expressed on the surface of leukocytes (except neutrophils). By binding to these integrins, natalizumab inhibits their interaction with vascular cell adhesion molecule-1 (VCAM-1) and mucosal addressin cell adhesion molecule-1 (MAdCAM-1) located on endothelial cells.

This blockade prevents leukocyte adhesion to the endothelium and subsequent transmigration across the endothelial barrier into inflamed tissues such as the central nervous system in multiple sclerosis, and the gut mucosa in Crohn’s disease. Hence, natalizumab effectively reduces the recruitment and infiltration of inflammatory immune cells into target tissues responsible for pathological inflammation and tissue damage.

At the cellular level, natalizumab inhibits the migration of activated T and B lymphocytes and monocytes into the brain parenchyma and gastrointestinal tract. This results in modulation of the immune response, decreasing demyelination and inflammatory lesions observed in MS, and reducing intestinal inflammatory activity in Crohn’s disease.

Compared with other disease-modifying therapies, natalizumab acts early in the leukocyte migration process, targeting adhesion rather than cytokine production or lymphocyte activation. Clinical studies demonstrate that natalizumab reduces relapse rates and lesion formation by disrupting immune cell trafficking. However, this mechanism also predisposes to rare but serious adverse events such as progressive multifocal leukoencephalopathy (PML) due to impaired central nervous system immune surveillance. Extensive ongoing research seeks to further elucidate integrin pathways and optimize risk-benefit profiles of such selective immunosuppressants.

Pharmacological Actions

Selective inhibition of alpha-4 integrins on leukocytes blocking interaction with endothelial adhesion molecules
Prevention of leukocyte adhesion and transmigration across vascular endothelium into inflamed tissues
Reduction of lymphocyte migration into central nervous system and gastrointestinal tract tissues
Immunomodulation by limiting inflammatory cell recruitment in autoimmune diseases
Decreased formation of demyelinating lesions in multiple sclerosis
Reduction of intestinal inflammation and maintenance of remission in Crohn’s disease
Altered immune surveillance potentially increasing susceptibility to opportunistic infections
Monoclonal antibody with specific high affinity binding to target integrins
Long circulating half-life enabling monthly dosing intervals
Competitive blockade of integrin receptors without direct cytotoxic effects
Modulation of immune cell trafficking without broad immunosuppression
Disruption of immune cell-endothelial interactions critical in inflammatory cascade

Therapeutic Or Clinical Uses

Treatment of relapsing forms of multiple sclerosis including clinically isolated syndrome, relapsing-remitting MS, and active secondary progressive MS in adults
Induction and maintenance therapy for moderately to severely active Crohn’s disease in adults with inadequate response to conventional therapies
Used as monotherapy in multiple sclerosis to reduce relapse rates and delay disease progression
Employed in Crohn’s disease patients who are intolerant or refractory to immunosuppressants and tumor necrosis factor (TNF)-alpha inhibitors
Reduction of new lesion formation in MS demonstrated by magnetic resonance imaging
Maintenance of clinical remission and reduction of inflammatory activity in Crohn’s disease
Part of treatment regimens requiring REMS program participation due to PML risk
Utilized in adult patients for whom other treatments have failed or are contraindicated
Clinical use restricted to specialized centers with appropriate monitoring protocols
Adjunct to corticosteroid tapering strategies in Crohn’s disease management
Employed when rapid and effective modulation of immune cell trafficking is indicated

Side Or Adverse Effects

Progressive multifocal leukoencephalopathy (PML), a rare but serious brain infection potentially leading to disability or death
Hypersensitivity reactions during or after infusion, including rash, urticaria, wheezing, hypotension, chest pain
Common adverse events: headache, fatigue, nausea, diarrhea, abdominal pain
Upper respiratory tract symptoms such as nasal congestion, sneezing, sore throat
Musculoskeletal pain including joint pain and extremity discomfort
Increased risk of infections due to immunosuppression, including viral infections
Elevated liver enzymes and signs of liver injury such as jaundice and dark urine
Unusual bruising or bleeding manifestations including nosebleeds and gum bleeding
Urinary tract infections and associated symptoms such as dysuria
Potential development of antibodies to natalizumab reducing efficacy and increasing infusion reactions
Post-infusion reactions including dizziness, nausea, sweating, lightheadedness
Rare reports of hematologic abnormalities including lymphopenia
Possible worsening of pre-existing malignancies not directly attributed but requires caution
Symptoms of hypersensitivity potentially delayed up to 2 hours or more after infusion
Risk of secondary autoimmune disorders is low but monitored

Precautions

Patients must be enrolled in the TOUCH Prescribing Program due to PML risk
Screening for John Cunningham Virus (JCV) antibodies prior to initiation and periodically during therapy
Avoid concurrent use with immunosuppressants or TNF-alpha inhibitors to reduce infection risk
Monitor closely for any signs or symptoms suggestive of central nervous system infections
Perform regular liver function tests to detect hepatotoxicity early
Assess patient history for prior immunosuppression, malignancies, or opportunistic infections
Use caution in patients with pre-existing compromised immune systems including HIV or AIDS
Pregnancy category not well-defined; risks and benefits must be weighed for pregnant women
Limited data available regarding safety during breastfeeding; consult healthcare provider
Not recommended for pediatric patients under 18 years old due to lack of safety data
Regular MRI evaluations recommended to monitor for early signs of PML or other neurologic changes
Observe patients post-infusion for at least one hour for hypersensitivity reactions
Patients should report fever, neurological changes, or infection symptoms immediately
Avoid exposure to individuals with active infections during treatment
Educate patients about potential adverse effects and importance of adherence to monitoring schedules

Warnings

Serious risk of progressive multifocal leukoencephalopathy (PML), which can be fatal or disabling
Higher risk of PML with treatment duration beyond 2 years, prior immunosuppressant use, or presence of anti-JCV antibodies
Immediate medical evaluation required if symptoms such as sudden fever, severe headache, confusion, vision changes, or motor weakness occur
Potential for severe allergic or anaphylactic reactions during or after infusion
Discontinue drug promptly if PML or other serious infections are suspected
Patients with history of PML or hypersensitivity to natalizumab should not receive the drug
Use in combination with other immunosuppressants or biological agents increases risk of infections and is contraindicated
Monitor for liver injury signs; discontinue if significant hepatotoxicity develops
Immunosuppression can increase susceptibility to bacterial, viral, fungal, or opportunistic infections
Pregnant or breastfeeding women should only use if clearly needed due to unknown fetal and infant risks
Continuous vigilance required for neurological symptoms suggestive of demyelinating disease worsening or CNS infections
Patients should be informed to avoid sick contacts and report infection signs immediately
Caution advised in patients with a history of cancer, lymphoma, or leukemia
Infusion-related adverse events may be serious and require emergency management
Delay or withhold subsequent doses if serious adverse reactions arise until cleared by treating physician

Contraindication

Known hypersensitivity or allergy to natalizumab or any component of the formulation
Prior or current diagnosis of progressive multifocal leukoencephalopathy (PML)
Concurrent use with immunosuppressant drugs such as 6-mercaptopurine, azathioprine, cyclosporine, or methotrexate in Crohn’s disease patients
Active severe infections or ongoing systemic infections at the time of planned treatment
Patients not registered or administering treatment outside the TOUCH Prescribing Program
Pediatric patients under 18 years due to insufficient safety and efficacy data
History of severe infusion-related hypersensitivity reactions to natalizumab
Use in patients with severely compromised immune systems without rigorous risk-benefit assessment
Known active malignancy or hematological cancers without stabilization or remission
Concurrent administration with TNF-alpha inhibitor biologics
Pregnancy contraindications if benefits do not outweigh risks as determined by treating physician
Any condition that may impair monitoring or ability to report neurological adverse events promptly
Severe hepatic impairment may warrant caution or alternative therapies
Contraindicated if patient has not undergone thorough infection and PML risk assessment prior to therapy
Use in patients with poorly controlled co-morbidities without appropriate specialist oversight

Drug Interactions

Increased risk of serious infections when combined with other immunosuppressants (e.g., azathioprine, methotrexate)
Concomitant use with TNF-alpha inhibitors such as infliximab or adalimumab is contraindicated due to additive immunosuppression
No significant cytochrome P450 enzyme interactions due to monoclonal antibody metabolism
Potential immunogenicity may alter effects of subsequent or prior biological therapies
Corticosteroids may be used concurrently with gradual tapering upon therapeutic response
Vaccinations may have reduced efficacy; live vaccines contraindicated during and shortly after natalizumab therapy
Concomitant use with chemotherapy or other immunomodulating agents requires careful clinical monitoring
Medications that suppress bone marrow function may increase risk of infections when used with natalizumab
Avoid combining with systemic agents that increase infection risk without strict clinical justification
No known direct interference with oral contraceptives or other small molecule drugs
Interactions with herbal or over-the-counter immunomodulatory supplements have not been extensively studied
Potential for increased hypersensitivity reactions if used with other antibody therapies
No known interaction with antacids or gastrointestinal medications as the drug is intravenously administered
Immunosuppressive effects may mask signs of infection from other medications
Patient counseling on drug interaction risks is critical due to potential severity of combined immunosuppression

Preparations Of The Drug

Tysabri (natalizumab) available as a single-dose vial containing 300 mg/15 mL (20 mg/mL) solution for intravenous infusion
Sterile, preservative-free liquid formulation supplied in glass vials for single use
Requires dilution or direct administration as per prescribing guidelines under healthcare supervision
Biosimilar product Tyruko (natalizumab-sztn) offers same dosage form and strength with similar therapeutic effects
Storage requirements include refrigeration at 2°C to 8°C and protection from light
Must be used promptly after preparation to preserve efficacy and stability
Distributed exclusively through the TOUCH Prescribing Program to ensure safe use
Administration requires specialized infusion equipment and trained medical personnel
No oral or subcutaneous formulations currently available
Formulations designed for IV delivery to achieve systemic therapeutic levels with controlled infusion rate
Commercially supplied in single-use vials minimizing contamination risk
Preparation for infusion includes aseptic technique and verification of patient identity and dose
Disposal of unused product should follow biohazard guidelines for monoclonal antibody therapies
No adjunctive agents included in vial; may be diluted in recommended infusion fluids as per protocol
Labeling and packaging include prominent warnings regarding PML and REMS program enrollment